Publications
Chosen filters:
Chosen filters:
Detection of gold nano-particles in atherosclerotic plaque using hyperspectral X-ray imaging Ghent University
Numerical simulation of salt transport and crystallization in drying Prague sandstone using an experimentally consistent multiphase model Ghent University
Performance of [F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease KU Leuven
Performance of the amyloid tracer [F]flutemetamol was evaluated against three pathology standard of truth (SoT) measures including neuritic plaques (CERAD "original" and "modified" and the amyloid component of the 2012 NIA-AA guidelines).
Coronary CT Angiography: Variability of CT Scanners and Readers in Measurement of Plaque Volume KU Leuven
Purpose To determine reader and computed tomography (CT) scan variability for measurement of coronary plaque volume. Materials and Methods This HIPAA-compliant study followed Standards for Reporting of Diagnostic Accuracy guidelines. Baseline coronary CT angiography was performed in 40 prospectively enrolled subjects (mean age, 67 years ± 6 [standard deviation]) with asymptomatic hyperlipidemia by using a 320-detector row scanner (Aquilion One ...
Influence of shear stress magnitude and direction on atherosclerotic plaque composition KU Leuven
The precise flow characteristics that promote different atherosclerotic plaque types remain unclear. We previously developed a blood flow-modifying cuff for ApoE(-/-) mice that induces the development of advanced plaques with vulnerable and stable features upstream and downstream of the cuff, respectively. Herein, we sought to test the hypothesis that changes in flow magnitude promote formation of the upstream (vulnerable) plaque, whereas ...
Inhibition of de novo plaque growth by a new 0.03Â % chlorhexidine mouth rinse formulation applying a non-brushing model: a randomized, double blind clinical trial KU Leuven
The aim of this study was to investigate the plaque inhibitory effect of a new 0.03 % chlorhexidine digluconate (CHX) and 0.05 % cetylpyridinium chloride (CPC) mouthrinse formulation and to explore patients' experience and side effects after its use.